Table 1.
Summary of randomised trials of neoadjuvant chemotherapy in esophageal cancer
| Trial/author | Year | No. of patients | Chemotherapy (cycles) | Histology |
|---|---|---|---|---|
| Roth | 1982 | 39 | Cisplatin/vindesine/bleomycin (2) | Squamous |
| Nygaard | 1983 | 81 | Cisplatin/bleomycin (2) | Squamous |
| Schlag | 1988 | 46 | Cisplatin/5-FU (3) | Squamous |
| Maipang | 1988 | 46 | Cisplatin/bleomycin (2) | Squamous |
| Law | 1989 | 147 | Cisplatin/5-FU (2) | Squamous |
| Boonstra | 1989 | 169 | Cisplatin/etoposide (2) | Squamous |
| Kelsen | 1990 | 467 | Cisplatin/5-FU (3) | Squamous/adeno |
| Ancona | 1992 | 96 | Cisplatin/5-FU (2) | Squamous |
| Allum | 1992 | 802 | Cisplatin/5-FU (2) | Squamous/adeno |
| Ychou | 1995 | 169 | Cisplatin/5-FU (6 periop) | Adeno |
Adapted with permission from Sjoquist KM et al.: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-92